



## (51) International Patent Classification:

*A61K 31/40* (2006.01) *A61K 9/00* (2006.01)*A61P 25/24* (2006.01) *A61K 45/06* (2006.01)

## (21) International Application Number:

PCT/IB2023/052082

## (22) International Filing Date:

06 March 2023 (06.03.2023)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

63/317,483 07 March 2022 (07.03.2022) US

## (71) Applicant: JANSSEN PHARMACEUTICALS, INC.

[US/US]; 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560 (US).

## (72) Inventors: SURMONT, Riccardo; Turnhoutseweg 30,

2340 Beerse (BE). SCHMIDT, Mark; Turnhoutseweg 30,

2340 Beerse (BE). POPOVA, Vanina; Turnhoutseweg 30,

2340 Beerse (BE). SAVITZ, Adam; 94 Birch Lane, Green-

wich, Connecticut 06830 (US). MELKOTE, Rama; 920

US Route 202, PO Box 300, Raritan, New Jersey 08869

(US). DREVETS, Wayne C.; 920 US Route 202, PO Box

300, Raritan, New Jersey 08869 (US). GOPAL, Srihari;

173 Berkley Avenue, Belle Mead, New Jersey 08502 (US).

PEMBERTON, Darrel; Turnhoutseweg 30, 2340 Beerse (BE). LAGISHETTY, Chakradhar; 920 US Route 202, PO Box 300, Raritan, New Jersey 08869 (US). KEZIC, Iva; Turnhoutseweg 30, 2340 Beerse (BE).

(74) Agent: LANE, David A. et al.; JOHNSON &amp; JOHNSON, One Johnson &amp; Johnson Plaza, New Brunswick, New Jersey 08933 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

## (54) Title: PURE FORMS OF CRYSTALLINE ATICAPRANT

**FIG. 2**

J10049



(57) Abstract: The disclosure provides compositions containing pure aticaprant, solvates of aticaprant, and methods of treating major depressive disorder using aticaprant.

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*